Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM).

Thromboembolic complications represent one of the most important cause of morbidity and mortality in cancer patients. Although several data have been published demonstrating the strong association between cancer and venous thromboembolism (VTE), there is poor perception, among oncologists, of the level of risk of thrombosis and of relevance of managing VTE in these patients. The Associazione Italiana di Oncologia Medica (AIOM) has provided some recommendations to direct clinical practice according to evidence-based data concerning cancer and VTE. In fact, we conducted an extensive literature review (1996-2005) to produce evidence-based recommendations to improve perceptions of the magnitude of this risk among Italian medical and surgical oncologists and alert on the new approaches to prophylaxis and treatment of VTE in cancer patients. Levels of evidence are given according to a five-point rating system, and similarly for each key recommendation a five-point rating system suggests if the evidence is strong and indicate that the benefits do, or do not, outweigh risks and burden.

[1]  R. Williamson,et al.  Prevention of Venous Thromboembolism in Cancer Patients , 1999, Seminars in thrombosis and hemostasis.

[2]  E. Bastounis,et al.  The incidence of occult cancer in patients with deep venous thrombosis: a prospective study , 1996, Journal of internal medicine.

[3]  J. Kuratsu,et al.  Expression of tissue factor correlates with grade of malignancy in human glioma , 1996, Cancer.

[4]  M. Monreal,et al.  Occult cancer in patients with acute pulmonary embolism. A prospective study. , 1993, Chest.

[5]  M. Prins,et al.  Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. , 2003, The New England journal of medicine.

[6]  J. Gore,et al.  Occult cancer in patients with acute pulmonary embolism. , 1982, Annals of internal medicine.

[7]  D. Bergqvist Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessme , 1997 .

[8]  M. Prins,et al.  Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. , 1997, The New England journal of medicine.

[9]  D. Heaton,et al.  Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis , 2002, Internal medicine journal.

[10]  P. Wells,et al.  Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection. , 1998, Archives of internal medicine.

[11]  D. Anderson,et al.  Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Unal,et al.  A randomized clinical trial of combination chemotherapy with and without low‐molecular‐weight heparin in small cell lung cancer , 2004, Journal of thrombosis and haemostasis : JTH.

[13]  H. Eriksson,et al.  Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. , 2000, Archives of internal medicine.

[14]  M. Monreal,et al.  Occult Cancer in Patients with Venous Thromboembolism: which Patients, which Cancers , 1997, Thrombosis and Haemostasis.

[15]  A. Encke,et al.  Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery , 1988, The British journal of surgery.

[16]  P. Benotti,et al.  Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. , 1990, Annals of internal medicine.

[17]  H. Büller,et al.  Low Molecular Weight Heparin and Compression Stockings in the Prevention of Venous Thromboembolism in Neurosurgery , 1996, Thrombosis and Haemostasis.

[18]  J. Hirsh,et al.  The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. , 1988, The New England journal of medicine.

[19]  A. Cohen,et al.  Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. , 2002, The New England journal of medicine.

[20]  J. Olsen,et al.  The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. , 1998, The New England journal of medicine.

[21]  M. Samama,et al.  Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis , 1988, The British journal of surgery.

[22]  M. Prins,et al.  Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. , 1992, The New England journal of medicine.

[23]  R. Rosell,et al.  Upper Extremity Deep Venous Thrombosis in Cancer Patients with Venous Access Devices - Prophylaxis with a Low Molecular Weight Heparin (Fragmin) , 1996, Thrombosis and Haemostasis.

[24]  E. Weiderpass,et al.  Venous thromboembolism and cancer , 1998, The Lancet.

[25]  J. Hirsh,et al.  A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. , 1996, The New England journal of medicine.

[26]  O. Guilbaud,et al.  Low molecular weight heparin given the evening before surgery compared with conventional low‐dose heparin in prevention of thrombosis , 1988, The British journal of surgery.

[27]  L. Zacharski,et al.  Heparin and Cancer , 1998, Thrombosis and Haemostasis.

[28]  Susanne M. Smorenburg,et al.  The Effects of Unfractionated Heparin on Survival in Patients with Malignancy – A Systematic Review , 1999, Thrombosis and Haemostasis.

[29]  J. Folkman Tumor angiogenesis and tissue factor , 1996, Nature Medicine.

[30]  R. Wolff,et al.  Venous thrombosis in cancer patients: insights from the FRONTLINE survey. , 2003, The oncologist.

[31]  M. Levine,et al.  The Thrombophilic State Induced by Therapeutic Agents in the Cancer Patient , 1999, Seminars in thrombosis and hemostasis.

[32]  R. Gray,et al.  Tamoxifen versus placebo: double-blind adjuvant trial in elderly women with stage II breast cancer. , 1986, NCI monographs : a publication of the National Cancer Institute.

[33]  D. Farge,et al.  Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. , 2002, Archives of Internal Medicine.

[34]  R J Hettiarachchi,et al.  Undiagnosed malignancy in patients with deep vein thrombosis , 1998, Cancer.

[35]  E. Medico,et al.  The MET oncogene drives a genetic programme linking cancer to haemostasis , 2005, Nature.

[36]  Joan S. Reisch,et al.  Prevention of Venous Thromboembolism in General Surgical Patients: Results of Meta‐analysis , 1988, Annals of surgery.

[37]  J. Hirsh,et al.  Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer , 1994, The Lancet.

[38]  A. Trousseau Phlegmasia alba dolens. , 1865 .

[39]  M. Prins,et al.  Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial , 2004, Journal of thrombosis and haemostasis : JTH.

[40]  B. Risberg,et al.  Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 Xal units in 2070 patients , 1995 .

[41]  M Gent,et al.  Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Armando Santoro,et al.  Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  S. Patierno,et al.  Tissue factor and fibrin in tumor angiogenesis. , 2004, Seminars in thrombosis and hemostasis.

[44]  A. Falanga,et al.  Pathophysiology of the Thrombophilic State in the Cancer Patient , 1999, Seminars in thrombosis and hemostasis.

[45]  J. Hirsh,et al.  A Comparison of the Safety and Efficacy of Oral Antiocoagulation for the Treatment of Venous Thromboembolic Disease in Patients with or without Malignancy , 2000, Thrombosis and Haemostasis.

[46]  V. Kakkar,et al.  Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery , 1993, The Lancet.

[47]  R. Brant,et al.  Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin , 1992, The Lancet.

[48]  S. Gordon,et al.  A factor X-activating cysteine protease from malignant tissue. , 1981, The Journal of clinical investigation.

[49]  Susanne M. Smorenburg,et al.  The effect of low molecular weight heparin on survival in patients with advanced malignancy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  M. Prins,et al.  Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  A. Falanga The effect of anticoagulant drugs on cancer , 2004, Current opinion in pulmonary medicine.

[52]  J. Boissel,et al.  Prevention of perioperative deep vein thrombosis in general surgery: A multicentre double blind study comparing two doses of Logiparin and standard heparin , 1991, The British journal of surgery.

[53]  J. Murchison,et al.  Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study , 2004, British Journal of Cancer.

[54]  A. Trousseau Clinique médicale de l'Hôtel-Dieu de Paris , 1877 .

[55]  Michael Thomas,et al.  Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  W. Ageno,et al.  Home-treatment of deep vein thrombosis in patients with cancer. , 2005, Haematologica.

[57]  A. Zelikovski,et al.  Idiopathic deep vein thrombosis in an apparently healthy patient as a premonitory sign of occult cancer , 1986, Cancer.

[58]  M. Monreal,et al.  Occult cancer in patients with deep venous thrombosis. A systematic approach , 1991, Cancer.

[59]  Z. Ahmed,et al.  Deep Vein Thrombosis as a Predictor of Cancer , 1996, Angiology.

[60]  B. Lindblad,et al.  Low molecular weight heparin once daily compared with conventional low‐dose heparin twice daily. A prospective double‐blind multicentre trial on prevention of postoperative thrombosis , 1986, The British journal of surgery.

[61]  S. Shirasawa,et al.  Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. , 2005, Blood.

[62]  W. Henderson,et al.  Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate: Final Report of VA cooperative study # 75 , 1984, Cancer.

[63]  M. Kovacs,et al.  Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. , 2001, The American journal of medicine.

[64]  J. Hirsh,et al.  Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. , 1998, Archives of internal medicine.

[65]  P. Bossuyt,et al.  Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. , 1996, The New England journal of medicine.

[66]  A. Falanga,et al.  Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. , 1985, Biochemistry.

[67]  P. Prandoni,et al.  Risk of Cancer in Patients Presenting with Venous Thromboembolism , 2004 .

[68]  C. Redmond,et al.  A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. , 1989, The New England journal of medicine.

[69]  G. Steger,et al.  Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[70]  F. Barral,et al.  A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. , 1998, The New England journal of medicine.

[71]  James N Ingle,et al.  American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  W. van Putten,et al.  Adjuvant portal liver infusion in colorectal cancer with 5‐fluorouracil/heparin versus urokinase versus control results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I) , 1990, Cancer.

[73]  S. Goldhaber,et al.  Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients , 2004, Circulation.

[74]  L. Melton,et al.  Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. , 2000, Archives of internal medicine.

[75]  S. Schulman,et al.  Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. , 2000, The New England journal of medicine.

[76]  H. Büller,et al.  The Effects of Vitamin K-antagonists on Survival of Patients with Malignancy: A Systematic Analysis , 2001, Thrombosis and Haemostasis.

[77]  B. Zee,et al.  Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  Susanne M. Smorenburg,et al.  Thrombosis prophylaxis in patient populations with a central venous catheter: a systematic review. , 2003, Archives of internal medicine.

[79]  L. Fielding,et al.  Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma , 1992, The Lancet.

[80]  Paolo Prandoni,et al.  Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. , 2002, Blood.

[81]  N. Lemoine,et al.  Tissue factor expression correlates with histological grade in human pancreatic cancer , 1995, The British journal of surgery.

[82]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[83]  A. Turpie,et al.  A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. , 1999, The New England journal of medicine.

[84]  A. Falanga,et al.  Deep vein thrombosis in cancer: the scale of the problem and approaches to management. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[85]  H. Dvorak Thrombosis and cancer. , 1987, Human pathology.